BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31334593)

  • 1. Commentary: SGLT inhibitors in type 1 diabetes: Place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis - the STOP DKA protocol.
    Rendell MS
    Diabetes Obes Metab; 2019 Oct; 21(10):2189-2191. PubMed ID: 31334593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol.
    Goldenberg RM; Gilbert JD; Hramiak IM; Woo VC; Zinman B
    Diabetes Obes Metab; 2019 Oct; 21(10):2192-2202. PubMed ID: 31183975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
    Burke KR; Schumacher CA; Harpe SE
    Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
    Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
    Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Colacci M; Fralick J; Odutayo A; Fralick M
    Can J Diabetes; 2022 Feb; 46(1):10-15.e2. PubMed ID: 34116926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.
    Liu H; Sridhar VS; Perkins BA; Rosenstock J; Cherney DZI
    Curr Diab Rep; 2022 Jul; 22(7):317-332. PubMed ID: 35633439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
    Peters AL; Henry RR; Thakkar P; Tong C; Alba M
    Diabetes Care; 2016 Apr; 39(4):532-8. PubMed ID: 26989182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials.
    Monami M; Nreu B; Zannoni S; Lualdi C; Mannucci E
    Diabetes Res Clin Pract; 2017 Aug; 130():53-60. PubMed ID: 28570924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On-label use of sodium-glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes.
    Horii T; Oikawa Y; Atsuda K; Shimada A
    J Diabetes Investig; 2021 Sep; 12(9):1586-1593. PubMed ID: 33448127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
    Goldenberg RM; Berard LD; Cheng AYY; Gilbert JD; Verma S; Woo VC; Yale JF
    Clin Ther; 2016 Dec; 38(12):2654-2664.e1. PubMed ID: 28003053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment.
    He Z; Lam K; Zhao W; Yang S; Li Y; Mo J; Gao S; Liang D; Qiu K; Huang M; Wu J
    Acta Diabetol; 2023 Mar; 60(3):401-411. PubMed ID: 36576563
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A series of diabetic ketoacidosis associated with the use of sodium-glucose co-transporter-2 inhibitors in secondary care.
    Taverner S; Eng C; Watson R; George S; Edwards A; Williams DM; Stephens JW
    Diabetes Metab Syndr; 2022 Dec; 16(12):102658. PubMed ID: 36371968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
    Danne T; Garg S; Peters AL; Buse JB; Mathieu C; Pettus JH; Alexander CM; Battelino T; Ampudia-Blasco FJ; Bode BW; Cariou B; Close KL; Dandona P; Dutta S; Ferrannini E; Fourlanos S; Grunberger G; Heller SR; Henry RR; Kurian MJ; Kushner JA; Oron T; Parkin CG; Pieber TR; Rodbard HW; Schatz D; Skyler JS; Tamborlane WV; Yokote K; Phillip M
    Diabetes Care; 2019 Jun; 42(6):1147-1154. PubMed ID: 30728224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor.
    Andrews TJ; Cox RD; Parker C; Kolb J
    J Emerg Med; 2017 Feb; 52(2):223-226. PubMed ID: 27717592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence, Cost, and Burden of Diabetic Ketoacidosis.
    Virdi N; Poon Y; Abaniel R; Bergenstal RM
    Diabetes Technol Ther; 2023 Jun; 25(S3):S75-S84. PubMed ID: 37306442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EUGLYCEMIC DIABETIC KETOACIDOSIS AND SEVERE ACUTE KIDNEY INJURY SECONDARY TO OFF LABEL USE OF SODIUM GLUCOSE COTRANSPORTER-2 INHIBITOR IN A TYPE-1 DIABETIC PATIENT.
    Tahir H; Wani A; Daruwalla V; Daboul N; Sagi J
    J Ayub Med Coll Abbottabad; 2015; 27(4):923-4. PubMed ID: 27004352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination.
    Jendle JH; Ampudia-Blasco FJ; Füchtenbusch M; Pozzilli P
    touchREV Endocrinol; 2021 Apr; 17(1):12-20. PubMed ID: 35118442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Euglycemic Diabetic Ketoacidosis Caused by a Sodium-glucose Co-transporter (SGLT) 2 Inhibitor after Coronary Artery Bypass Grafting].
    Kameda Y; Kato M; Inoue B; Yamazaki S; Sahara N; Aoki T; Nagashima Y; Nemoto N; Anzai H; Araki W; Kobayashi N
    Kyobu Geka; 2019 May; 72(5):354-357. PubMed ID: 31268032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis.
    Hampp C; Swain RS; Horgan C; Dee E; Qiang Y; Dutcher SK; Petrone A; Chen Tilney R; Maro JC; Panozzo CA
    Diabetes Care; 2020 Jan; 43(1):90-97. PubMed ID: 31601640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors and prevention strategies for diabetic ketoacidosis in people with established type 1 diabetes.
    Ehrmann D; Kulzer B; Roos T; Haak T; Al-Khatib M; Hermanns N
    Lancet Diabetes Endocrinol; 2020 May; 8(5):436-446. PubMed ID: 32333879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.